Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in‐depth review of mechanisms of action, failure factors, and future perspectives

Documents similaires

• Parent's perception of respiratory syncytial virus and subsequent wheezing burden: A multi‐country cross‐sectional survey
  par: Adnan Custovic, et autres
  Publié: (2024)
• Age‐specific predictors of disease severity in children with respiratory syncytial virus infection beyond infancy and through the first 5 years of age
  par: Helena Brenes‐Chacon, et autres
  Publié: (2024)
• Short‐ and mid‐term morbidity and primary‐care burden due to infant respiratory syncytial virus infection: A Spanish 6‐year population‐based longitudinal study
  par: Sonia Ares‐Gómez, et autres
  Publié: (2024)
• Viral and non‐viral episodes of wheezing in early life and the development of asthma and respiratory phenotypes among urban children
  par: Tara N. Havens, et autres
  Publié: (2024)
• Early‐life allergic sensitization and respiratory infection—Two hits on lung function?
  par: Vikas Wadhwa, et autres
  Publié: (2025)